Get the Stockscreener App
8.90
1.37%
0.12
Pre-market:
8.92
0.02
+0.22%
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols Sa Adr stock is traded at $8.90, with a volume of 218.20K.
It is up +1.37% in the last 24 hours and down -3.47% over the past month.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
See More
Previous Close:
$8.78
Open:
$8.82
24h Volume:
218.20K
Relative Volume:
0.35
Market Cap:
$6.06B
Revenue:
$7.94B
Net Income/Loss:
$225.54M
P/E Ratio:
26.98
EPS:
0.3299
Net Cash Flow:
$709.16M
1W Performance:
+1.37%
1M Performance:
-3.47%
6M Performance:
+5.33%
1Y Performance:
+22.25%
1-Day Range:
$8.77
$9.015
1-Week Range:
$7.64
$9.015
52-Week Range:
$6.19
$11.14
Grifols Sa Adr Stock (GRFS) Company Profile
Name
Grifols Sa Adr
Sector
Industry
Phone
-
Address
-
Compare GRFS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
8.90 | 5.97B | 7.94B | 225.54M | 709.16M | 0.3299 |
|
LLY
Lilly Eli Co
|
1,014.49 | 925.06B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.48 | 494.70B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
228.71 | 406.92B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.43 | 256.58B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.89 | 253.84B | 63.90B | 19.05B | 13.05B | 7.5596 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Resumed | Morgan Stanley | Overweight |
| Mar-12-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-12-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-16-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-18-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-08-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-05-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-19-21 | Downgrade | Barclays | Overweight → Underweight |
| Oct-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-14-21 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-20-21 | Initiated | Deutsche Bank | Hold |
| Mar-23-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-11-21 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-01-20 | Upgrade | Citigroup | Sell → Neutral |
| Jun-09-20 | Downgrade | Citigroup | Neutral → Sell |
| Jun-09-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Mar-25-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-08-19 | Downgrade | Berenberg | Buy → Hold |
| Oct-11-18 | Upgrade | Berenberg | Hold → Buy |
| Jun-01-18 | Initiated | Barclays | Overweight |
| Oct-31-17 | Initiated | Citigroup | Buy |
| Jun-30-17 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-17 | Initiated | BofA/Merrill | Buy |
| Jan-03-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-09-16 | Upgrade | Berenberg | Hold → Buy |
| Jan-04-16 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-02-15 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-20-15 | Downgrade | Berenberg | Buy → Hold |
| Apr-28-15 | Downgrade | Berenberg | Buy → Hold |
View All
Grifols Sa Adr Stock (GRFS) Latest News
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols (NASDAQ:GRFS) Share Price Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Plasma Derived Medicine Market to Reach USD 37.4 Billion by 2034, Growing at 8.05% CAGR - GlobeNewswire Inc.
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
CNH Industrial NV (NYSE: CNH) Stock Forecast: Bearish Sentiment Points To -15.21% Downside In 2025 - stocksregister.com
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
Oppenheimer Asset Management Inc. Acquires 23,980 Shares of Grifols, S.A. (NASDAQ:GRFS) - Defense World
ADMA Biologics Vs. Grifols: Which Plasma Therapy Stock Is The Better Buy? - Barchart.com
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar Australia
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks | Morningstar UK - Morningstar Canada
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - PR Newswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Grifols, S.A. - GlobeNewswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Grifols, - GlobeNewswire
GRFS Stock Quote Price and Forecast - CNN
Grifols S.A. Investigated by Block & Leviton For Potential - GlobeNewswire
Which Trades Are Top Funds Making? - Morningstar Canada
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - Newswire Canada
8 Newly Undervalued 5-Star Stocks - Morningstar
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation - Stock Titan
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021 - PR Newswire
GRFS Pivot Points, Technical Analysis and Moving AveragesGrifols SaAdrLevel Iii Technicals - CMLviz
GRFS Financial Statements & ChartsGrifols SaAdrLevel Iii MacroTrends - CMLviz
Grifols Class B: Buy The Recovery In The U.S. Plasma Business (NASDAQ:GRFS) - Seeking Alpha
Grifols SA Share Price ADR each Representing 1 Non Voting B Share - Hargreaves Lansdown
Grifols, S.A. Stock (GRF)Quote BME - marketscreener.com
Grifols Sa Adr Stock (GRFS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):